-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The anti-tumor biopharmaceutical Boyouno® (bevacizumab injection) developed by Boan Bio, a subsidiary of Luye Pharmaceutical Group, was officially launched in China on June 5.
Bevacizumab injection is a representative anti-tumor angiogenesis drug.
As a biosimilar of Bevacizumab, Boyouno® has undergone a head-to-head comparison with the original drug in two key clinical studies, that is, a pharmacokinetic PK comparison study in healthy volunteers.
"In clinical research, Boyouno® has shown good efficacy and safety, which is highly similar to the original drug.
In recent years, the number of cancer cases in my country has been on the rise.
Anti-angiogenic drugs are one of the indispensable methods in the treatment of malignant tumors.
Professor Liang Jun from Peking University International Hospital said: “Bevacizumab can be used in combination with many other treatment methods, and its combined treatment model has many advantages, and it continues to play a role in the treatment of non-small cell lung cancer, colorectal cancer and other malignant tumors.
In order to further improve the accessibility and affordability of treatment for patients, Boan Bio and Beijing Kangmeng Charity Foundation jointly launched the "Boyouno® Patient Relief Project".
